GPT and hepatocellular carcinoma: In terms of the safety findings, previous studies of patients with intermediate to advanced HCC treated with PD-1 inhibitor plus TACE indicated that the most common adverse events included fever, skin reactions, fatigue, vomiting, hypertension, diarrhea, thrombocytopenia, elevated AST, elevated ALT, asthenia, decreased appetite, rash, and pruritus (12, 28).